Revenue distribution by sectors:

• Animal health: 60%
• Agricultural biotechnology: 25%
• Other biotechnology applications: 15%

TOP 3 markets and their percentage shares:

• China: 50%
• USA: 20%
• Europe: 15%

Jinyu Bio-technology Co., Ltd. generates the majority of its revenue from the animal health sector, which is attributed to its specialized products and services in this area. The Chinese market is the largest single market for the company, supported by strong local presence and demand for animal health solutions in China.

The USA and Europe follow as important markets, with both regions benefiting from the growing demand for innovative biotechnological solutions. The company has established a presence in these markets through strategic partnerships and expansions.

Production Sites: Mainly in China (As of 2023)

Jinyu Bio-technology Co., Ltd. is a Chinese company specializing in the production of biotechnological products. The main production facilities are located in China, where the company has continuously expanded its capacities to meet the increasing demand. It is known for its advanced production plants and compliance with international standards in biotechnology.

Current Growth Strategy: Diversification and International Expansion

Jinyu Bio-technology Co., Ltd. is pursuing a strategy of diversification and international expansion to secure future growth. The company plans to further expand its product range in the field of animal health, particularly through the development of new vaccines and diagnostic solutions.

Another focus is on tapping into new markets outside of China. Jinyu Bio-technology is investing in establishing production facilities and distribution networks in Asia and Africa to meet the increasing demand for veterinary medical products there.

Additionally, the company places great emphasis on research and development to promote innovative technologies and products that are intended to secure long-term competitive advantages. This also includes strategic partnerships with international research institutions and companies.

Main raw materials: Biochemical reagents, specific proteins, enzymes

Main importing countries: USA, Germany, Japan

Jinyu Bio-technology Co., Ltd. mainly imports biochemical reagents, specific proteins, and enzymes needed for their biotechnological applications. These raw materials are essential for the production of diagnostics and other biotechnological products.

The USA, Germany, and Japan are the main suppliers of these materials. These countries are known for their advanced biotechnological research and production, which explains the high quality and specialization of the imported raw materials. Importing from these countries ensures Jinyu Bio-technology access to high-quality materials crucial for their production processes.

Market share: 25% (estimated, 2026)

Research & Development (R&D) expenses: 10% of revenue (2025)

Jinyu Bio-technology Co., Ltd. has a significant competitive advantage in the biotechnology industry, especially in China. The company holds an estimated market share of 25%, indicating its strong position in the animal health and biopharmaceutical sectors.

A key factor contributing to this advantage is the continuous investment in research and development, accounting for approximately 10% of revenue. These investments enable Jinyu to develop and launch innovative products, enhancing its competitiveness.

Additionally, the company benefits from strategic partnerships and a strong presence in emerging markets, further solidifying its market position. The competitive advantage is supported by a combination of technological innovation, market knowledge, and an effective sales strategy.

Institutional Investor Share: 45% (estimated, 2026)
Insider Buys/Sells: No significant transactions in the last year (estimated, 2026)

The institutional investor share in Jinyu Bio-technology Co., Ltd. is estimated to be around 45%. This suggests that a significant number of shares are held by large financial institutions, indicating a certain level of confidence in the company's stability and growth potential.

Regarding insider buys and sells, there were no significant transactions in the last year. This could indicate that the management and other insiders do not currently expect significant changes in the company's value or that they are satisfied with the current corporate strategy.

Market share of Jinyu Bio-technology Co., Ltd.: 8% (2026, estimated)

Top competitors and their market shares:

1. Zoetis Inc.: 18%
2. Boehringer Ingelheim Animal Health: 15%
3. Elanco Animal Health: 12%
4. Merck Animal Health: 10%
5. Jinyu Bio-technology Co., Ltd.: 8%
6. Bayer Animal Health: 7%
7. Virbac: 5%
8. Ceva Santé Animale: 4%
9. Vetoquinol: 3%
10. Phibro Animal Health: 2%

Moat of Jinyu Bio-technology Co., Ltd.:

Jinyu Bio-technology Co., Ltd. has a moderate moat, mainly based on its strong position in the Asian market, especially in China. The company benefits from deep local market knowledge and established relationships with regional partners and customers.

Compared to larger international competitors like Zoetis and Boehringer Ingelheim, which have extensive global distribution networks and a wide range of products, Jinyu's moat is less pronounced. These competitors often have the advantage of larger research and development budgets as well as a stronger global brand presence.

However, Jinyu could remain competitive through specialized products and innovations in specific niche markets. The focus on regional adaptations and rapid response to local market needs could also be seen as strategic advantages.

Revenue Growth: 18% (2025) Profit Growth: 14% (2025) Research and Development Ratio: 10% of revenue (2025)

Jinyu Bio-technology Co., Ltd. recorded strong revenue growth of 18% in 2025, driven by increased demand for its biotechnological products and services. Profit growth was at 14%, indicating efficient cost controls and improved production capacity.

The company continues to invest in research and development, with 10% of revenue allocated to innovative projects. This suggests that Jinyu Bio-technology is striving to expand its product range and explore new markets.

In summary, Jinyu Bio-technology Co., Ltd. demonstrates positive financial development and a strong commitment to innovation, indicating long-term growth potential. This could make the stock an attractive investment, especially for investors interested in the long-term development in the biotechnology sector.

Dividend Yield: 2.5% (estimated for 2026)
Dividend History: Stable payouts over the last 5 years

Jinyu Bio-technology Co., Ltd. has regularly distributed dividends in recent years. The dividend yield is estimated to be around 2.5% for 2026, based on the latest available data and the company's past payout policy.

The company has maintained a stable dividend policy over the last five years, indicating a reliable distribution. Jinyu Bio-technology's financial stability and consistent profits support this practice. Analysts expect the company to continue its dividend policy unless significant economic or company-specific challenges arise.